US37733W2044
© BusinessWire
21.01.2026
GSK
LISTED
NYSE
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
News Preview
GSK plc (LSE/NYSE: GSK) today announced the 2025 recipients of its COiMMUNITY Initiative grant program, awarding a total of $2 million across 16 state, regional and national non-profits working to improve immunization rates across the US. Through COiMMUNITY, GSK invests in local efforts to improve vaccine education and uptake. Now in its third yea...
Themefolio
Profiler
Peergroup
© BusinessWire
20.01.2026
GSK
LISTED
NYSE
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
News Preview
GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and local non-profit organizations working to improve the lives of people impacted by lupus, including systemic lupus erythematosus (SLE) and lupus nephritis (LN).
GSK previously sough...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
GSK
LISTED
NYSE
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
News Preview
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
The FDA approval of Exdensur is based on data from the SWIFT-1 and S...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
24.10.2025
GSK
LISTED
NYSE
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
News Preview
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhi...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
01.10.2025
GSK
LISTED
NYSE
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
News Preview
GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends across 387 different metro areas* to get insights on adult immunization at the local level. Vaccine Track now also includes a full de...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
GSK
LISTED
NYSE
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
News Preview
GSK plc (LSE/NYSE: GSK) announced its sponsorship of the 2025 National Senior Games as part of its nationwide Sideline RSV campaign, a health education campaign aimed at helping educate older adults and their loved ones about the risks of respiratory syncytial virus, or RSV. The National Senior Games give adults over 50 across the US the opportuni...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
GSK
LISTED
NYSE
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
News Preview
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1....
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
GSK
LISTED
NYSE
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
News Preview
GSK plc (LSE/NYSE: GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK’s Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m. CT, Pretty Hurts features a storyline that aims to raise awareness among parents about meningococcal disease, known as m...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
GSK
LISTED
NYSE
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchase...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
GSK
LISTED
NYSE
Deadline Soon: GSK plc. (GSK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclus...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
GSK
LISTED
NYSE
GSK Deadline: Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022. GSK is a “global pharmaceutical company that develops, manufactures, and markets vaccines and medicines wo...
Themefolio
Profiler
Peergroup
© BusinessWire
17.02.2025
GSK
LISTED
NYSE
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the f...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.02.2025
GSK
LISTED
NYSE
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (t...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
GSK
LISTED
NYSE
Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).
IF YOU AR...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
GSK
LISTED
NYSE
Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
GSK
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusiv...
Themefolio
Profiler
Peergroup
© BusinessWire
09.02.2025
GSK
LISTED
NYSE
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the f...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
GSK
LISTED
NYSE
Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff m...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
GSK
LISTED
NYSE
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchas...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
GSK
LISTED
NYSE
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GSK PLC. (GSK), CLICK HE...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
GSK
LISTED
NYSE
GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOV...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
GSK
LISTED
NYSE
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”).
For more information, submit a form, email attorney Phillip Kim, or g...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
GSK
LISTED
NYSE
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GSK PLC. (GSK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
GSK
LISTED
NYSE
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
News Preview
GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone (BVd) versus daratumumab in combination with bortezomib plus dexamethasone (DVd) as a secon...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
